Literature DB >> 11525885

Do immune cells promote the pathology of dystrophin-deficient myopathies?

M J Spencer1, J G Tidball.   

Abstract

Many features of dystrophin-deficient muscle pathology are not clearly related to the loss of mechanical support of the muscle membrane by dystrophin. In the present review, evidence that supports a role for the immune system in promoting the pathology of dystrophinopathy is presented. The findings summarized here indicate that specific, cellular immune responses by cytotoxic T-lymphocytes and helper T-lymphocytes contribute to muscle pathology in dystrophin-deficient muscle, and that removal of specific lymphoid cell populations can reduce muscle pathology. In addition, innate immune responses may also promote dystrophinopathies by the tremendous infiltration of myeloid cell populations into the dystrophic muscle. Loss of normal redox homeostasis by dystrophin-deficient muscle may increase its sensitivity to free radical-mediated damage by myeloid cells. Collectively, the observations presented here suggest that the contribution of the immune system to dystrophinopathies may be significant, and that therapeutic approaches based upon immune interventions may ameliorate the pathological progression of dystrophin deficiency.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2001        PMID: 11525885     DOI: 10.1016/s0960-8966(01)00198-5

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  64 in total

1.  Lack of the serum- and glucocorticoid-inducible kinase SGK1 improves muscle force characteristics and attenuates fibrosis in dystrophic mdx mouse muscle.

Authors:  Martin Steinberger; Michael Föller; Silke Vogelgesang; Mirjam Krautwald; Martin Landsberger; Claudia K Winkler; Joachim Kasch; Ernst-Martin Füchtbauer; Dietmar Kuhl; Jakob Voelkl; Florian Lang; Heinrich Brinkmeier
Journal:  Pflugers Arch       Date:  2014-11-14       Impact factor: 3.657

2.  Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.

Authors:  D M Escolar; A Zimmerman; T Bertorini; P R Clemens; A M Connolly; L Mesa; K Gorni; A Kornberg; H Kolski; N Kuntz; Y Nevo; C Tesi-Rocha; K Nagaraju; S Rayavarapu; L P Hache; J E Mayhew; J Florence; F Hu; A Arrieta; E Henricson; R T Leshner; J K Mah
Journal:  Neurology       Date:  2012-03-07       Impact factor: 9.910

3.  The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.

Authors:  Mahmoud R Hussein; Sherifa A Hamed; Mohammed G Mostafa; Eman E Abu-Dief; Nageh Fouly Kamel; Mahmoud R Kandil
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

4.  Markers of degeneration and regeneration in Duchenne muscular dystrophy.

Authors:  E Abdel-Salam; I Abdel-Meguid; S S Korraa
Journal:  Acta Myol       Date:  2009-12

5.  Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice.

Authors:  Akhilesh Kumar; Shephali Bhatnagar; Ashok Kumar
Journal:  Am J Pathol       Date:  2010-05-14       Impact factor: 4.307

6.  Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy.

Authors:  Saurabh Dahiya; Srikanth Givvimani; Shephali Bhatnagar; Natia Qipshidze; Suresh C Tyagi; Ashok Kumar
Journal:  J Immunol       Date:  2011-08-01       Impact factor: 5.422

7.  Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.

Authors:  Ingrid E C Verhaart; Hans Heemskerk; Tatyana G Karnaoukh; Ingrid G M Kolfschoten; Anne Vroon; Gert-Jan B van Ommen; Judith C T van Deutekom; Annemieke Aartsma-Rus
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

8.  Splenic Ly6Chi monocytes are critical players in dystrophic muscle injury and repair.

Authors:  Giuseppe Rizzo; Rosanna Di Maggio; Anna Benedetti; Jacopo Morroni; Marina Bouche; Biliana Lozanoska-Ochser
Journal:  JCI Insight       Date:  2020-01-30

9.  Three-dimensional optical coherence micro-elastography of skeletal muscle tissue.

Authors:  Lixin Chin; Brendan F Kennedy; Kelsey M Kennedy; Philip Wijesinghe; Gavin J Pinniger; Jessica R Terrill; Robert A McLaughlin; David D Sampson
Journal:  Biomed Opt Express       Date:  2014-08-22       Impact factor: 3.732

10.  Adeno-associated virus serotype 8 (AAV8) delivery of recombinant A20 to skeletal muscle reduces pathological activation of nuclear factor (NF)-κB in muscle of mdx mice.

Authors:  Rakshita A Charan; Gabriela Niizawa; Hiroyuki Nakai; Paula R Clemens
Journal:  Mol Med       Date:  2013-02-08       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.